Andros Pharmaceuticals Co.,Ltd
6917
Rank in Stocks
#22698
Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise,... Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the advancement of novel drug delivery platform technologies. Its development pipeline features APC101, a metered-dose, quick-drying, film-forming spray undergoing Phase IIa clinical investigation for the management of pain linked to post-herpetic neuralgia. Also in development is APC201, an innovative topical anesthetic formulation currently in Phase I/II trials for Osteoarthritis treatment, alongside an siRNA (small interfering RNA) compound functioning as an antisense oligonucleotide and DNA candidate. In the preclinical phase, the company is advancing APC310 and APC501, both intended as anesthetics for intravenous catheter insertion and venipuncture. Another preclinical asset, APC401, is a specialized emulsified solution targeting post-surgical pain relief. Beyond its developmental programs, Andros Pharmaceuticals also provides LALP cream for dermal analgesic use, iMinos solution for treating Alopecia Androgenetica, and T4 endonuclease V. Established in 2008, the firm maintains its headquarters in Zhubei, Taiwan.
Share Price
$0.92063065
Last synced: 2026-11-10
Market Cap
$50.61M
Change (1 day)
-1.79%
Change (1 year)
35.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Andros Pharmaceuticals Co.,Ltd (6917)
Category
Healthcare
EPS for Andros Pharmaceuticals Co.,Ltd (6917)
EPS as of June 2026 TTM: $-0.02
According to Andros Pharmaceuticals Co.,Ltd's latest financial reports, its current EPS (TTM) is $-0.02. At the end of 2025 the company had an EPS of $-0.04, an increase over its 2024 EPS of $-0.07.
EPS history for Andros Pharmaceuticals Co.,Ltd from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.02 | -51.50% |
| 2025 | $-0.04 | -43.51% |
| 2024 | $-0.07 | 7.55% |
| 2023 | $-0.06 | 49.26% |
| 2022 | $-0.04 | -17.41% |
| 2021 | $-0.05 | 4.44% |
| 2020 | $-0.05 | -35.12% |
| 2019 | $-0.07 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -80,821.65% |
US
|
|
| $-7.07 | 36,343.30% |
US
|
|
| $-5.29 | 27,168.04% |
AU
|
|
| $12.88 | -66,492.27% |
BE
|
|
| $21.56 | -111,234.02% |
NL
|
Questions about Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS)
What is Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS)?
Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS) over the last twelve months is $-0.02, as of Jun 2026.
What was Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS) in 2025?
In 2025, Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS) was $-0.04, compared with $-0.07 in 2024.
How has Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS) was highest in 2025 ($-0.04) and lowest in 2024 ($-0.07).
How does Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS) compare with similar companies?
Andros Pharmaceuticals Co.,Ltd's earnings per share (EPS) ($-0.02) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.